New Weight Loss Drug Semaglutide Linked to Improved Mental Health in Sweden

A significant Swedish study has revealed that GLP-1 weight loss medications, particularly semaglutide, are associated with notable improvements in mental health among patients with depression and anxiety. The research, involving over 95,000 Swedish individuals diagnosed with depression or anxiety between 2009 and 2022, found that semaglutide use correlates with a 42% reduction in the risk of sick leave and hospital care related to mental health issues.

Researchers from Karolinska Institutet, Östra Finlands Universitet, and Griffith University analyzed data from national registers, comparing periods of medication use with non-use. The study highlighted a 44% reduction in risk for depression, 38% for anxiety, and 47% for substance use disorders during semaglutide treatment. Liraglutid, another GLP-1 medication, was linked to an 18% lower risk, while other GLP-1 drugs did not show significant benefits.

This research suggests GLP-1 drugs may help decrease mental health-related sick leave and care needs, with a general association to reduced self-harm risk. However, Jari Tiihonen, a Karolinska Institutet professor, called for controlled clinical trials to confirm these observational findings.

Simultaneously, a new semaglutide-containing oral weight-loss pill approved in the USA has raised hope for easier treatment options in Sweden. Overläkare Ylva Trolle Lagerros indicated this more affordable pill could soon become available, making weight loss treatment more accessible compared to injectable forms like Ozempic. This development is expected to simplify healthcare practices while maintaining effective weight loss results.

These advancements point to a promising intersection between obesity treatment and mental health improvement, with semaglutide playing a central role in Sweden’s medical landscape moving forward.